Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review
- PMID: 40337725
- PMCID: PMC12058109
- DOI: 10.1159/000545498
Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review
Abstract
Introduction: Fibrillary glomerulonephritis (FGN) is a rare form of immune complex-mediated primary glomerular disease frequently coexisting with malignancies or autoimmune diseases. The kidney prognosis is extremely poor, with approximately 50% of patients progressing to end-stage kidney disease within 2-4 years after diagnosis. However, no established treatment currently exists.
Case presentation: Here we describe a rare case of FGN diagnosed in a patient progressing from monoclonal gammopathy to multiple myeloma. The histopathological findings of the kidney biopsy were consistent with classical FGN and revealed no evidence of myeloma cast nephropathy. Albumin-dominant, Bence Jones protein-negative proteinuria further supported this diagnosis. The patient was successfully treated with anti-myeloma chemotherapies including autologous stem cell transplant, resulting in significant improvement in kidney function.
Conclusion: Based on our experience, secondary FGN associated with plasma cell neoplasms may represent a rare entity that responds favorably to anti-myeloma therapies. Initial investigations to rule out coexistent plasma cell neoplasms are crucial for the optimal management of FGN patients.
Keywords: Fibrillary glomerulonephritis; Kidney biopsy; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Plasma cell neoplasms.
© 2025 The Author(s). Published by S. Karger AG, Basel.
Conflict of interest statement
M.K. received research funding from Pfizer, Otsuka Pharmaceutical, Chugai Pharmaceutical, Astellas, Kyowa Kirin, Takeda Pharmaceutical, Teijin, Eisai, Sumitomo Dainippon Pharma, Nippon Shinyaku, AbbVie, Daiichi Sankyo, and Ono Pharmaceutical; advisory fees from Kyowa Kirin, Celgene, Chugai Pharmaceutical, and MSD; and lecture fees from MSD, Astellas, Otsuka Pharmaceutical, Ono Pharmaceutical, Celgene, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Chugai Pharmaceutical, Janssen Pharmaceutical, Kyowa Kirin, AbbVie, Pfizer, AstraZeneca, Bristol-Myers Squibb, Amgen, Sanwa Kagaku, Sanofi, SymBio Pharmaceutical, and Nippon Shinyaku. None of these are related to the current study. M.N. received research funding from Chugai Pharmaceutical, Astellas, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe, JT, and Torii and honorarium and advisory fees from Kyowa Kirin, Chugai Pharmaceutical, Astellas, Daiichi Sankyo, Mitsubishi Tanabe, JT, Boehringer Ingelheim, Astra Zeneca, and GSK. None of these are related to the current study.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
